Compare BGS & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGS | ASMB |
|---|---|---|
| Founded | 1996 | 2005 |
| Country | United States | United States |
| Employees | 86 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.5M | 440.0M |
| IPO Year | 2004 | 2010 |
| Metric | BGS | ASMB |
|---|---|---|
| Price | $5.92 | $29.85 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.38 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 2.3M | 94.4K |
| Earning Date | 06-03-2026 | 01-01-0001 |
| Dividend Yield | ★ 15.05% | N/A |
| EPS Growth | ★ 83.02 | 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,828,687,000.00 | N/A |
| Revenue This Year | N/A | $33.33 |
| Revenue Next Year | $0.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.67 | $7.76 |
| 52 Week High | $8.06 | $39.71 |
| Indicator | BGS | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 72.78 | 54.68 |
| Support Level | $3.98 | $29.31 |
| Resistance Level | N/A | $31.27 |
| Average True Range (ATR) | 0.25 | 1.75 |
| MACD | 0.02 | 0.33 |
| Stochastic Oscillator | 67.25 | 84.06 |
B&G Foods Inc is an American packaged-food manufacturer. It operate in a single industry segment and manufacture, sell and distribute a diverse portfolio of high-quality shelf-stable and frozen foods across the United States, Canada and Puerto Rico. Its products include frozen and canned vegetables, vegetable, canola and other cooking oils, vegetable shortening, cooking sprays, oatmeal and other hot cereals, fruit spreads, canned meats and beans, bagel chips, spices, seasonings, hot sauces, wine vinegar, The company's main brands are Ac'cent, B&G, B&M, Baker's Joy, Bear Creek Country Kitchens, Cary's, Cream of Rice, Cream of Wheat, Devonsheer, Don Pepino, Durkee, Emeril's, Grandma's Molasses, MacDonald's.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.